UNSPSC 51434301: Piretanide

This classification denotes a loop diuretic with the molecular formula C17H18N2O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DQ6KK6GV93, chemically known as benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(pyrrolidinyl)- but generally known as piretanide, which bears US NIH Compound Identifier 4849. European Medicines Agency schedules Piretanide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09906MIG.

UNSPSC 51434301 Piretanide is a Commodity code that captures state and local procurement of specific pharmaceutical compounds for emergency medical and health system use. While the code nominally names piretanide, a diuretic agent, the recent opportunities record show state and local bodies purchasing a broader range of advanced life support medications, generic pharmaceuticals, and over-the-counter products through cooperative and direct procurement channels. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing consortia (Minnesota Multistate Cooperative Purchasing Alliance). The work centers on supplying medications with strict expiration and shelf-life requirements, often bundled with wholesaler distribution agreements, cGMP and DSCSA compliance certification, and performance warranties.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026 for Advanced Life Support Medications—four medication line items totaling approximately 3,530 units for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000, including a 5 percent Small Local Business Enterprise bid discount. Texas HHS Commission posted an RFI (No. HHS0017013) on April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs for the state's pharmacy benefit system, with no formal award value or timeline established at that stage. Minnesota's cooperative purchasing alliance (MMCAP) issued an RFP (S1070000015802) due March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, with award effective July 1, 2026 and a two-year initial term. The code shows fragmented, episodic purchasing across jurisdictions rather than sustained high-volume demand under a single issuer.